3,5-Dimethyl-4-pentan-3-yloxy-2-(2,4,6-trimethylphenoxy)pyridine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3,5-Dimethyl-4-pentan-3-yloxy-2-(2,4,6-trimethylphenoxy)pyridine
• 化学式: C₂₁H₂₉NO₂
• 分子量: 327.5
• InChiKey: KQTTXQPSDUEFLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Composite materials for controlled release of water soluble products
  申请人：Ying Y. Jackie

  公开号：US20060024377A1

  公开（公告）日：2006-02-02

  Composite materials comprising a water-soluble compound adsorbed onto a basic inorganic material and a bio-degradable polymer which yields acidic degradation products, methods of producing same, and methods of use thereof are described, wherein the composite materials are designed so as to provide controlled release of the water soluble molecule.

  本发明涉及一种复合材料，包括吸附在碱性无机材料上的水溶性化合物和可生物降解聚合物，其产生酸性降解产物，描述了其制备方法和使用方法，其中复合材料的设计旨在提供水溶性分子的控制释放。
• Osmotic delivery system
  申请人：——

  公开号：US20030175346A1

  公开（公告）日：2003-09-18

  An osmotic pharmaceutical tablet is described which comprises a single-layer compressed core surrounded by a water permeable layer having a passageway. The single-layer core contains (i) a non-ripening drug having a solubility per dose less than about 1 mL −1 , (ii) about 2.0% to about 20% by weight of a hydroxyethylcellulose having a weight-average, molecular weight from about 300,000 to about 2,000,000, and (iii) an osmagent.

  描述了一种渗透性制药片，其包括一个被可渗透水层包围的单层压缩核心，该可渗透水层具有一个通道。单层核心包含（i）一种每剂溶解度小于约1 mL-1的非成熟药物，（ii）约2.0％至约20％重量的羟乙基纤维素，其重量平均分子量约为300,000至2,000,000，以及（iii）渗透剂。
• Compositions Containing Antiviral Compounds and Methods of Using the Same
  申请人：Cantrell Gary L.

  公开号：US20090258843A1

  公开（公告）日：2009-10-15

  The present invention is directed to compositions and methods for the treatment of various diseases, pathological disorders, and medical conditions such as viral infections and cancer. The compositions include (A) an antiviral compound or a pharmaceutically acceptable salt thereof; and (B) an agent selected from the group consisting of a substituted or unsubstituted imidazole or a pharmaceutically acceptable salt thereof; a non-steroidal anti-inflammatory agent or a pharmaceutically acceptable salt thereof; an amino acid or a pharmaceutically acceptable salt thereof; a carboxylic acid or a pharmaceutically acceptable salt thereof; a sulfonic acid or a pharmaceutically acceptable salt thereof; and a combination thereof.

  本发明涉及用于治疗各种疾病、病理障碍和医疗条件，如病毒感染和癌症的组合物和方法。所述组合物包括（A）抗病毒化合物或其药学上可接受的盐；和（B）从以下组中选择的药剂：取代或未取代的咪唑或其药学上可接受的盐；非甾体抗炎药或其药学上可接受的盐；氨基酸或其药学上可接受的盐；羧酸或其药学上可接受的盐；磺酸或其药学上可接受的盐；或其组合物。
• Pharmaceutical Compositions With Enhanced Performance
  申请人：Babcock Walter C.

  公开号：US20080262107A1

  公开（公告）日：2008-10-23

  Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability.

  本发明涉及羟丙基甲基纤维素乙酸琥珀酸酯（HPMCAS）和羟丙基甲基纤维素乙酸酯（HPMCA）的聚合物，其羟丙氧基，甲氧基，乙酰基和琥珀酰基取代度独特。当用于制备包含低溶解度药物和这些聚合物的组合物时，这些聚合物提供了增强的水溶液浓度和/或改善的物理稳定性。
• PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERFORMANCE
  申请人：Babcock Walter C.

  公开号：US20120264833A1

  公开（公告）日：2012-10-18

  Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) and hydroxypropyl methyl cellulose acetate (HPMCA) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility drug and such polymers, the polymers provide enhanced aqueous concentrations and/or improved physical stability.

  本发明涉及羟丙基甲基纤维素醋酸琥珀酸酯(HPMCAS)和羟丙基甲基纤维素醋酸酯(HPMCA)的聚合物，其羟丙氧基、甲氧基、乙酰基和琥珀酰基取代度独特。当用于制备含低溶解度药物和上述聚合物的组合物时，聚合物提供了增强的水溶液浓度和/或改善的物理稳定性。